New consensus research on neuropathological aspects of familial amyotrophic lateral sclerosis with superoxide dismutase 1 (SOD1) gene mutations: Inclusions containing SOD1 in neurons and astrocytes

被引:137
|
作者
Kato, S
Takikawa, M
Nakashima, K
Hirano, A
Cleveland, DW
Kusaka, H
Shibata, N
Kato, M
Nakano, I
Ohama, E
机构
[1] Tottori Univ, Fac Med, Inst Neurol Sci, Div Neuropathol, Yonago, Tottori 6838504, Japan
[2] Tottori Univ, Fac Med, Inst Neurol Sci, Div Neurol, Yonago, Tottori 6838504, Japan
[3] Tottori Univ, Fac Med, Dept Pathol 2, Yonago, Tottori 6838504, Japan
[4] Montefiore Med Ctr, Div Neuropathol, Bronx, NY USA
[5] Univ Calif San Diego, Ludwig Inst Canc Res, San Diego, CA 92103 USA
[6] Univ Calif San Diego, Dept Med, San Diego, CA 92103 USA
[7] Univ Calif San Diego, Dept Neurosci, San Diego, CA 92103 USA
[8] Kansai Med Univ, Dept Neurol, Moriguchi, Osaka 570, Japan
[9] Tokyo Womens Med Coll, Dept Pathol, Tokyo 162, Japan
[10] Jichi Med Coll, Dept Neurol, Minami Kawachi, Tochigi, Japan
来源
AMYOTROPHIC LATERAL SCLEROSIS | 2000年 / 1卷 / 03期
关键词
familial amyotrophic lateral sclerosis (FALS); neuronal Lewy-body-like hyaline inclusions (LBHIs); astrocytic hyaline inclusions (Ast-Hls); superoxide dismutase 1 (SOD1); granule-coated fibrils;
D O I
10.1080/14660820050515160
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that primarily involves the motor neuron system. Approximately 5-10% of ALS is familial. Superoxide dismutase 1 (SOD1) gene mutations are shown to be associated with about 20% of familial ALS (FALS) patients. The neuronal Lewy-body-like hyaline inclusion (LBHI) and astrocytic hyaline inclusion (Ast-HI) are morphological hallmarks of certain SOD1-linked FALS patients with SOD1 gene mutant and transgenic mice expressing human SOD1 with G85R mutation. From the detailed immunohistochemical analyses, the essential common protein of both inclusions is SOD1. Ultrastructurally, both inclusions consist of granule-coated fibrils 15-25 nm in diameter. Based on the immune-electron microscopical finding that these abnormal granule-coated fibrils are positive for SOD1, the formation (or aggregation) of the abnormal fibrils containing SOD1 would be essential evidence in diseases caused by various SOD1 mutations. The granule-coated fibrils are also modified by advanced glycation end products (AGEs). The AGEs themselves are insoluble molecules with direct toxic effects on cells. AGE formation of SOD1 composing the granule-coated fibrils (probable AGE-modified mutant SOD1) may amplify their aggregation and produce a more marked toxicity.
引用
下载
收藏
页码:163 / 184
页数:22
相关论文
共 50 条
  • [31] Pathological heterogeneity of familial amyotrophic lateral sclerosis with SOD1 gene mutation
    Tomiyasu, H
    Yanagita, M
    Llena, JF
    Weidenheim, KM
    Hirano, A
    BRAIN PATHOLOGY, 2000, 10 (04) : 625 - 625
  • [32] Mutations in Superoxide Dismutase 1 (Sod1) Linked to Familial Amyotrophic Lateral Sclerosis Can Disrupt High-Affinity Zinc-Binding Promoted by the Copper Chaperone for Sod1 (Ccs)
    Boyd, Stefanie D.
    Ullrich, Morgan S.
    Calvo, Jenifer S.
    Behnia, Fatemeh
    Meloni, Gabriele
    Winkler, Duane D.
    MOLECULES, 2020, 25 (05):
  • [33] α-Synuclein coaggregation in familial amyotrophic lateral sclerosis with SOD1 gene mutation
    Takei, Yo-ichi
    Oguchi, Kenya
    Koshihara, Hiroshi
    Hineno, Akiyo
    Nakamura, Akinori
    Ohara, Shinji
    HUMAN PATHOLOGY, 2013, 44 (06) : 1171 - 1176
  • [34] Formation of advanced glycation end-product-modified superoxide dismutase-1 (SOD1) is one of the mechanisms responsible for inclusions common to familial amyotrophic lateral sclerosis patients with SOD1 gene mutation, and transgenic mice expressing human SOD1 gene mutation
    Kato, S
    Nakashima, K
    Horiuchi, S
    Nagai, R
    Cleveland, DW
    Liu, J
    Hirano, A
    Takikawa, M
    Kato, M
    Nakano, I
    Sakoda, S
    Asayama, K
    Ohama, E
    NEUROPATHOLOGY, 2001, 21 (01) : 67 - 81
  • [35] Silence superoxide dismutase 1 (SOD1): a promising therapeutic target for amyotrophic lateral sclerosis (ALS)
    Abati, Elena
    Bresolin, Nereo
    Comi, Giacomo
    Corti, Stefania
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2020, 24 (04) : 295 - 310
  • [36] Amyotrophic lateral sclerosis: a new missense mutation in the SOD1 gene
    Tortelli, Rosanna
    Conforti, Francesca Luisa
    Cortese, Rosa
    D'Errico, Eustachio
    Distaso, Eugenio
    Mazzei, Rosalucia
    Ungaro, Carmine
    Magariello, Angela
    Gambardella, Antonio
    Logroscino, Giancarlo
    Simone, Isabella Laura
    NEUROBIOLOGY OF AGING, 2013, 34 (06) : 1709.e3 - 1709.e5
  • [37] SOD1 gene mutations in amyotrophic lateral sclerosis Italian patients.
    Gellera, C
    Testa, D
    Passariello, P
    Mineri, R
    Morandi, L
    Sabatelli, M
    Munerati, E
    Corbo, M
    Mariotti, C
    Silani, V
    Di Donato, S
    Taroni, F
    AMERICAN JOURNAL OF HUMAN GENETICS, 2003, 73 (05) : 547 - 547
  • [38] Changes in mitochondrial protein expression attributable to the presence of mutant superoxide dismutase 1 (SOD1) in a cell-culture model of SOD1 familial amyotrophic lateral sclerosis (FALS)
    Wood-Allum, CA
    Allen, S
    Shaw, PJ
    NEUROLOGY, 2004, 62 (07) : A186 - A186
  • [39] Disease penetrance in amyotrophic lateral sclerosis associated with mutations in the SOD1 gene
    Andersen, PM
    Restagno, G
    Stewart, HG
    Chiò, A
    ANNALS OF NEUROLOGY, 2004, 55 (02) : 298 - 299
  • [40] Modification of Superoxide Dismutase 1 (SOD1) Properties by a GFP Tag - Implications for Research into Amyotrophic Lateral Sclerosis (ALS)
    Stevens, James C.
    Chia, Ruth
    Hendriks, William T.
    Bros-Facer, Virginie
    van Minnen, Jan
    Martin, Joanne E.
    Jackson, Graham S.
    Greensmith, Linda
    Schiavo, Giampietro
    Fisher, Elizabeth M. C.
    PLOS ONE, 2010, 5 (03): : A8 - A17